We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · February 09, 2021

Long-Term Safety of Palbociclib Plus Endocrine Therapy for HR-Positive/HER2-Negative Advanced Breast Cancer

The Oncologist

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Long-Term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis With Up to 5 Years of Follow-Up
Oncologist 2021 Jan 23;[EPub Ahead of Print], RS Finn, HS Rugo, KA Gelmon, M Cristofanilli, M Colleoni, S Loi, P Schnell, DR Lu, KP Theall, A Mori, E Gauthier, E Bananis, NC Turner, V Diéras

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading